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phosphorylation ratio Ser1177/Thr497 of
endothelial nitric oxide synthase in diabetic mice
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Background: Azilsartan, an angiotensin II type 1 (AT1) receptor blocker (ARB), has a higher affinity for and slower
dissociation from AT1 receptors and shows stronger inverse agonism compared to other ARBs. Possible benefits of
azilsartan in diabetic vascular dysfunction have not been established.
Methods: We measured vascular reactivity of aortic rings in male KKAy diabetic mice treated with vehicle, 0.005%
azilsartan, or 0.005% candesartan cilexetil for 3 weeks. Expression of markers of inflammation and oxidative stress
was measured using semiquantitative RT-PCR in the vascular wall, perivascular fat, and skeletal muscle.
Phosphorylation of endothelial nitric oxide synthase (eNOS) at Ser1177 and Thr495 was measured using Western blotting, and
the ratio of phosphorylation at Ser1177 to phosphorylation at Thr495 was used as a putative indicator of vascular eNOS activity.
Results: (1) Vascular endothelium–dependent relaxation with acetylcholine in KKAy mice was improved by azilsartan
treatment compared to candesartan cilexetil; (2) the ratio of Ser1177/Thr495 phosphorylation of eNOS was impaired in KKAy
and was effectively restored by azilsartan; (3) anomalies in the expression levels of monocyte chemotactic protein 1 (MCP1),
F4/80, NAD(P)H oxidase (Nox) 2, and Nox4 of the aortic wall and in the expression of TNFα in the perivascular fat were
strongly attenuated by azilsartan compared to candesartan cilexetil.
Conclusions: These results provide evidence that azilsartan prevents endothelial dysfunction in diabetic mice, more potently
than does candesartan cilexetil. Azilsartan’s higher affinity for and slower dissociation from AT1 receptors may underlie its
efficacy in diabetic vascular dysfunction via a dual effect on uncoupled eNOS and on Nox.Introduction
In patients with type 2 diabetes mellitus (T2DM), both
macrovascular and microvascular disease cause extensive
morbidity and mortality [1,2]. Treatment with angiotensin-
converting enzyme inhibitors [3] and angiotensin II type 1
(AT1) receptor blockers (ARBs) [4] improves both macro-
vascular and microvascular outcomes in patients with
T2DM. The renin–angiotensin system (RAS), a hormonal* Correspondence: mshimabukuro-ur@umin.ac.jp
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article, unless otherwise stated.cascade that includes angiotensinogen, renin, angiotensin-
converting enzyme, angiotensin, and its receptors is in-
volved in the maintenance of systemic blood pressure.
Alternatively, angiotensin II functions as a local biologically
active mediator in the progression of cardiovascular re-
modeling through the AT1 receptor [5]. Therefore, ARBs
are thought to have cardioprotective effects beyond their
antihypertensive effects. In a diabetic state, excessive sys-
temic production of angiotensin II or predominant intra-
crine or intracellular RAS activation might be involved in
the progression of vascular complications [6,7]. Therefore,ntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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crucial for understanding diabetic vascular complications.
Endothelial nitric oxide synthase (eNOS) is a nitric oxide
synthase that generates nitric oxide (NO) in blood vessels
and is involved with regulating vascular tone by inhibiting
smooth muscle contraction [8]. Loss of NO bioavailability is
believed to indicate a dysfunctional phenotype across broad
properties of the endothelium. Thus, the assessment of its
vasodilator properties resulting from NO can provide infor-
mation on the integrity and function of the endothelium.
Such endothelial dysfunction is implicated in the pathogen-
esis of cardiovascular diseases of type 2 diabetes [9].
Enzymatic activity of eNOS is regulated by multiple
phosphorylation of specific sites on the eNOS protein [10].
The most well-studied are the functional consequences of
phosphorylation of Ser1177 and Thr495. Ser1177 is a positive
regulatory site of eNOS, and Thr495 is a negative regulatory
site of eNOS in that phosphorylation leads to increase or
decreased enzymatic activity [10]. It has been reported that
drugs interfering with the renin-angiotensin–aldosterone
system enhances eNOS phosphorylation at Ser1177 and
improves NO bioavailability [11,12]. However, these bene-
ficial effects of RAS blockade are not inspected in diabetic
models. Reactive oxidant species (ROS), which are pro-
duced at a high rate in the diabetic and/or insulin resistant
obese state [13], can cause oxidative damage of cellular
components and activate several pathways linked with
inflammation. RAS have been identified in different or-
gans, most notably in those playing a significant role in
metabolism and insulin sensitivity, including the liver,
skeletal muscle and adipose and perivascular tissue. It has
been reported that inhibition of RAS reduce ROS produc-
tion pathways such as Nox2, a major catalytic component
of an endothelial NADPH oxidase [14], and Nox4, a com-
ponent of endothelial and smooth muscle NADPH oxidase
[15], proinflammatory markers such as tumor necrosis
factor α (TNFα) [16], monocyte chemotactic protein 1
(MCP1) [16], F4/80 (a marker for mature macrophages and
monocytes) [17] and improve adipocyte-expression of per-
oxisome proliferator–activated receptor γ2 (PPARγ2), the
ligand-activated nuclear hormone receptor [18], insulin
receptor substrate 1 (IRS-1) [19], and adiponectin [20].
A new ARB, azilsartan, was recently approved and is
expected to exert a more potent, sustained for 24 h BP-
lowering effect compared to existing ARBs (candesartan
cilexetil, olmesartan, telmisartan, valsartan, and irbesartan)
[21]. In an in vitro study, it has been shown that azilsartan
has higher affinity for and slower dissociation from AT1 re-
ceptors [22] and shows stronger inverse agonism [23]. These
effects of azilsartan on the AT1 receptor may underlie its
superior BP-lowering properties (compared to other ARBs)
and may be beneficial in diabetic vascular remodeling.
The present study was designed to compare the efficacy
of azilsartan and candesartan cilexetil against abnormalitiesin vascular reactivity and eNOS phosphorylation (which
reflects eNOS inactivation [24-26]) and against ROS and
inflammatory activation in the vascular wall, perivascular
fat, and skeletal muscle in a murine diabetic model.
Materials and methods
Animals and the protocol
Eight-week-old male KKAy mice (Clea Japan Inc., Tokyo,
Japan) were randomly distributed into 3 treatment groups
so that the groups had similar average blood glucose level
and body weight. The mice were fed a standard moderate-
fat (MF) diet or an MF diet mixed with 0.005% candesartan
cilexetil or 0.005% azilsartan (Takeda Pharmaceutical
Co., Ltd., Osaka, Japan) for 3 weeks (KKAy-Vehicle,
KKAy-Azilsartan, and KKAy-Candesartan groups). Age-
matched C57BL/6 J male mice (SLC Japan) were used
as a control group (C57BL/6 J-Vehicle group). Based on a
report showing that two-week treatment with candesartan
cilexetil had a cardioprotective effects in 8-week-old KKAy
mice [27], we chose a 3-week treatment period in 8-week
old KKAy mice. Body weight, food intake, and systolic
blood pressure were checked weekly. Blood pressure was
measured using a tail cuff system (Softron, Co., Tokyo). At
the end of the experimental period, we collected plasma,
subcutaneous fat, visceral fat, liver, pancreas, soleus muscle,
quadriceps muscle, thoracic aorta, and perivascular fat
around the thoracic aorta and stored them at -80°C until
analysis. Blood glucose levels were measured by a glucose
meter, plasma insulin levels by a mouse insulin ELISA kit
(Shibayagi Co.,Ltd., Gunma, Japan) and uric acid by a uric
acid assay kit (Cayman Chemical, Ann Arbor, USA). Mice
were housed in a light- and temperature-controlled room
in a 12-hour light/dark cycle. All animal experiments
were approved by the Committee on Animal Research,
the University of Tokushima and have been conducted
in accordance with international ethical principles and
guidelines for experiments on animals.
The glucose tolerance test and insulin tolerance test
After 2 weeks of treatment, glucose tolerance test (GTT)
and insulin tolerance test (ITT) were performed. In GTT,
the mice were given an intraperitoneal injection of 1 gram
of glucose per kilogram of body weight after 16 hours of
overnight fasting. Blood glucose levels were measured in 0,
15, 30, 60, 90, and 120 min. In ITT, the mice were given an
injection of 0.75 or 1 unit of insulin per kilogram of body
weight after 4 hours of fasting on post-GTT Day 3. Insulin
sensitivity was estimated by percent changes in the plasma
glucose concentration.
Vascular reactivity
The analysis of vascular reactivity was performed as de-
scribed previously [28]. Briefly, the periadventitial tissue
of the descending thoracic aorta was dissected away under
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(KHB; 118.4 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2,
1.2 mM KH2PO4, 1.2 mM MgSO4, 25 mM NaHCO3,
11.1 mM glucose) and cut transversely into ~2.0-mm-long
ring segments. The aortic rings were placed in a tissue
chamber filled with KHB (37°C) bubbled with 90% O2–5%
CO2 and were mounted onto 2 tungsten wires for meas-
urement of isometric tension. Initial tension was set at
0.7 g, and the rings were allowed to equilibrate as the
chambers were refilled with fresh KHB every 15 min.
Cumulative concentration–response curves for acetylcho-
line (Ach; 10-9 M to 10-4 M) and sodium nitroprusside
(SNP; 10-9 M to 10-4 M) were generated after induction of
an approximately 60% contraction with phenylephrine
(Phe) of maximal contraction caused by 31.4 mM KCl.
Western blotting analysis
For immunoblotting, we homogenized tissues in RIPA buf-
fer (Wako Pure Chemical Industries, Ltd., Tokyo) contain-
ing protease inhibitors (Takara Bio Inc., Shiga, Japan) and a
phosphatase inhibitor (Nacalai Tesque, Kyoto, Japan)
and collected the supernatants. Proteins (5 μg/lane) were
separated on 5–20% gradient SDS–polyacrylamide gels
and transferred onto polyvinylidene difluoride membranes
(GE Healthcare Bio Sciences, Piscataway, NJ). After block-
ing with TBS-T buffer containing either 3% bovine serum
albumin or 5% skim milk, the membranes were incubated
with antibodies against phospho-eNOS (Ser1177, 1:1000,
Cell Signaling Technology, Beverly, MA), phospho-eNOS
(Thr495, 1:1000, Cell Signaling Technology) and total eNOS
(1:1000, BD Biosciences, San Diego, CA) or a peroxidase-
conjugated antibody against β-actin (1:50000, Sigma–
Aldrich, St. Louis, MO) [29] and antibody binding was
detected with horseradish peroxidase-conjugated secondary
antibodies (1:2000; Chemicon) using an enhanced chemilu-
minescence system (GE Healthcare Japan, Tokyo). The
band intensity of phospho-eNOS (Ser1177 and Thr495) was
scanned in gray scale at the maximum resolution of at least
600 dpi using NIH Image J 1.47 and arbitrary ratio normal-
ized to the band intensity of total-eNOS were used.
Semiquantitative RT-PCR analysis
After extraction of total RNA from aorta, perivascular
fat, and soleus muscle, we synthesized cDNA, using the
QuantiTect Reverse Transcription kit (Qiagen, Valencia, CA)
and then, performed real-time RT-PCR with gene-specific
primers and SYBR green dye on an Applied Biosystems
7500 Real-Time PCR System (Life Technologies Japan
Ltd, Tokyo). The forward (fwd) and reverse (rev) primer
sequences are as follows: TNFα [30] (fwd: 5′-ACCCTCA
CACTCAGATCATCTTC-3′; rev: 5′-TGGTGGTTTGCT
ACGACGT-3′), MCP1 [30] (fwd: 5′-CCACTCACCTGC
TGCTACTCAT-3′; rev: 5′-TGGTGATCCTCTTGTAGC
TCTCC-3′), F4/80 [17] (fwd: 5′-TGCATCTAGCAATGGACAGC-3′; rev: 5′-GCCTTCTGGATCCATTTGAA -3′),
Nox2 [14] (fwd: 5′-ACTCCTTGGGTCAGCACTGG-3′;
rev: 5′-GTTCCTGTCCAGTTGTCTTGG-3′), Nox4 [15]
(fwd: 5′-TGTTGGGCCTAGGATTGTGTT-3′; rev: 5′-
AGGGACCTTCTGTGATCCTCG-3′), adiponectin (fwd:
5′-ATGGCAGAGATGGCACTCCT-3′; rev: 5′-CCTTC
AGCTCCTGTCATTCCA-3′), PPARγ2 [18] (fwd: 5′-GAR
GGAAGACCACTCGCATT-3′; rev: 5′-AACCATTGGG
TCAGCTCTTG -3′), IRS-1 [19] (fwd: 5′-GCCAGAGGA
TCGTCAATAGC-3′; rev: 5′-AAGACGTGAGGTCCTGG
TTG-3′), and β-actin (fwd: 5′-CCTGAGCGCAAGTACTC
TGTGT-3′; rev: 5′-GTCGATCCACATCTGCTGGAA-3′).
Statistical analysis
Data were calculated as mean ± SEM. All analyses were
performed using the Prism software (version 6.0d, GraphPad
Software, La Jolla, CA, USA). Two-way analysis of variance
was used for the changes of systolic blood pressure and body
weight in the course of administration, and for GTT and
ITT. Differences between multiple groups were analyzed by
one-way analysis of variance or the Kruskal–Wallis test in
the case of non-Gaussian distribution, followed by the
Tukey's post hoc test for comparison between treatment
groups. Differences with p < 0.05 were considered statis-
tically significant and with p < 0.01 significant.
Results
General characteristics
As shown in Table 1, body weight increased to the same
extent in KKAy mice treated with vehicle, candesartan
cilexetil, or azilsartan, and blood pressure was reduced
comparably by candesartan cilexetil and azilsartan. In
GTT, blood glucose levels in KKAy mice were higher at
baseline and were strongly elevated after a glucose load
compared to age-matched C57BL/6 J (Figure 1). In ITT,
blood glucose levels did not decrease after an insulin in-
jection in KKAy mice. Treatment with either candesartan
cilexetil or azilsartan in KKAy mice did not change the
response curves in GTT and ITT. Plasma levels of uric
acid increased comparably in KKAy mice treated with
vehicle, candesartan cilexetil, or azilsartan as compared
to C57BL/6 J (Table 1). Weight of subcutaneous and
visceral fat and of the liver was elevated and weight of
the soleus and quadriceps muscles decreased in KKAy
mice. Those metrics were not changed by candesartan
cilexetil and azilsartan treatment (Table 1).
Effects on vascular function in KKAy mice
As shown in Figure 2, vascular endothelium–dependent
relaxation in response to acetylcholine in KKAy mice
was improved significantly by azilsartan, but not by cande-
sartan cilexetil. The half-maximal effective concentration
(EC50) for acetylcholine was -8.06 ± 0.16 (log10 mol/L) in
vehicle-treated KKAy, -8.31 ± 0.16 in candesartan-treated
Table 1 General characteristics
C57BL6J-Vehicle KKAy-Vehicle KKAy-Candesartan KKAy-Azilsartan
Number 7 9 9 8
Body weight
baseline (g) 22.4 ± 0.4 36.5 ± 1.3 37.2 ± 1.6 37.0 ± 1.6
1 week (g) 23.9 ± 0.6 41.2 ± 0.8 †† 40.8 ± 0.9 †† 41.3 ± 0.9 ††
2 week (g) 24.3 ± 0.6 40.5 ± 0.7 †† 40.5 ± 0.9 †† 40.6 ± 0.9 ††
3 week (g) 25.1 ± 0.8 43.8 ± 0.6 †† 43.1 ± 0.9 †† 43.0 ± 0.8 ††
Systolic blood pressure
baseline (mmHg) 101 ± 1 101 ± 3 100 ± 2 102 ± 2
1 week (mmHg) 100 ± 2 109 ± 2 † 82 ± 3 ** 84 ± 3 **
2 week (mmHg) 102 ± 1 104 ± 2 81 ± 2 ** 82 ± 2 **
3 week (mmHg) 99 ± 2 108 ± 2 † 79 ± 2 ** 82 ± 3 **
Fasting blood glucose
baseline (mg/dL) 53 ± 4 75 ± 21 78 ± 8 77 ± 7
2 week (mg/dL) 63 ± 4 139 ± 22 † 104 ± 10 † 138 ± 14 †
Plasma uric acid
3 week (μmol/L) 6.5 ± 1.8 18.7 ± 1.5 † 18.4 ± 3.0 † 18.0 ± 2.5 †
Tissue weight (g/g)
subcutaneous fat/body weight 0.015 ± 0.002 0.040 ± 0.001 †† 0.038 ± 0.002 †† 0.042 ± 0.001 ††
visceral fat/body weight 0.014 ± 0.001 0.025 ± 0.001 †† 0.024 ± 0.001 †† 0.028 ± 0.001 ††
liver/body weight 0.047 ± 0.002 0.064 ± 0.002 †† 0.058 ± 0.002 †† 0.066 ± 0.001 ††
soleus muscle/body weight 0.013 ± 0.000 0.008 ± 0.000 †† 0.009 ± 0.000 †† 0.007 ± 0.000 ††
quadriceps muscle/body weight 0.014 ± 0.001 0.009 ± 0.000 †† 0.010 ± 0.000 †† 0.009 ± 0.000 ††
Values are mean ± SEM. **p<0.01 vs KKAy-Vehicle. † p<0.05 and †† p<0.01 vs C57BL6J-Vehicle.
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azilsartan-treated KKAy (p = 0.005 compared to vehicle).
Constriction in response to phenylephrine and
endothelium-independent relaxation in response to so-
dium nitroprusside did not differ among vehicle-, cande-
sartan cilexetil–, and azilsartan-treated KKAy mice.
Effects on total eNOS and eNOS phosphorylation at
Ser1177 and Thr495
Phosphorylation at Ser1177, a positive regulatory site of
eNOS associated with increased enzymatic activity [10],Figure 1 Glucose tolerance test (GTT) and insulin tolerance test (ITT). G
(MF) diet (KKAy-Vehicle, ○) and MF mixed with 0.005% candesartan cilexetil (K
weeks since 8–9 weeks of age. Age-matched C57BL/6 J male mice were usedtended to be decreased, and phosphorylation at Thr495,
a negative regulatory site of eNOS associated with decreased
enzymatic activity [10], tended to be increased in KKAy
mice compared to control mice (C57BL/6 J). Although
changes in phosphorylation signals either at Ser1177 or
Thr495 did not reach statistical significance, the ratio of
phosphorylation at Ser1177 to phosphorylation at Thr495
was statistically significantly lower in KKAy mice (Figure 3).
Compared to candesartan cilexetil, azilsartan was effect-
ive at restoring the phosphorylation ratio Ser1177/Thr495
(p < 0.05 compared to KKAy-vehicle).TT and ITT were performed in male KKAy mice fed standard moderate fat
KAy-Candesartan groups, □) or 0.005% azilsartan (KKAy-Azilsartan, ●) for 2
as a control group (△). The data are shown as mean ± SEM.
Figure 2 Vascular reactivity in aorta ring. Vascular reactivity to phenylephrine, acetylcholine, or sodium nitroprusside was determined using
aortic rings isolated from male KKAy mice fed standard moderate fat (MF) diet (KKAy-Vehicle, ○) and MF mixed with 0.005% candesartan cilexetil
(KKAy-Candesartan groups, □) or 0.005% azilsartan (KKAy-Azilsartan, ●) for 3 weeks since 8–10 weeks of age. Data represent the mean ± SEM. *p < 0.05,
KKAy-vehicle versus KKAy-Azilsartan.
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and soleus muscle
In the aortic wall of KKAy mice, mRNA expression of
MCP1, a representative inflammatory cytokine [16], of
F4/80, a marker for mature macrophages and monocytes
[17], of Nox2, a major catalytic component of an endothe-
lial NADPH oxidase [14], and of Nox4, a component of
endothelial and smooth muscle NADPH oxidase [15],
tended to be increased in KKAy mice compared to control
mice (C57BL/6 J; Figure 4, upper panel). These levels of
mRNA expression were strongly reduced by azilsartan
compared to candesartan cilexetil. Expression of PPARγ2,
the ligand-activated nuclear hormone receptor [18], was de-
creased in KKAy, but was not altered by either candesartan
cilexetil or azilsartan. In the perivascular fat, mRNA expres-
sion of TNFα, MCP1, and Nox2 was increased in KKAyFigure 3 Relative intensity of total eNOS and eNOS phosphorylation
phosphorylation at Ser1177 to at Thr495 (Ser1177p/Thr495p; lower panel
mice fed standard moderate fat (MF) diet (Veh) and MF mixed with 0.005%
8–10 weeks of age, Western blotting analysis were made. Age-matched C5
membranes were incubated with antibodies against phospho-eNOS (Ser117
(Thr495, 1:1000, Cell Signaling Technology) and total eNOS (1:1000, BD Biosc
horseradish peroxidase-conjugated secondary antibodies (1:2000; Chemico
Japan, Tokyo). The band intensity of phospho-eNOS (Ser1177 and Thr495) wa
using NIH Image J 1.47 and arbitrary ratio normalized to the band intensity
compared to C57BL/6 J and +p < 0.1 and *p < 0.05 compared to KKAy-vehimice (Figure 4, middle panel), and these anomalies in the
expression of TNFα and Nox2 were attenuated only by azil-
sartan. In the soleus muscle of KKAy, mRNA expression
levels of TNFα, MCP1, and NOX2 were increased and that
of IRS-1 [19] was decreased (p < 0.05 compared to the con-
trol group C57BL6J-Vehicle), and these anomalies of KKAy
mice were not attenuated by either candesartan cilexetil or
azilsartan (Figure 4, lower panel).
Discussion
The major findings of the present study are as follows:
(1) vascular endothelium–dependent relaxation in response
to acetylcholine in KKAy mice was improved strongly by
azilsartan compared to candesartan cilexetil; (2) the ratio of
Ser1177/Thr495 phosphorylation of eNOS, a putative marker
for eNOS activation was impaired in KKAy mice, and theat Ser1177 (Ser1177p) and Thr495 (Thr495p) and the ratio of eNOS
) in aorta. Using proteins (5 μg/lane) of aorta isolated from male KKAy
candesartan cilexetil (Can) or 0.005% azilsartan (Azi) for 3 weeks since
7BL/6 J male mice were used as a control group. After transfer, the
7, 1:1000, Cell Signaling Technology, Beverly, MA), phospho-eNOS
iences, San Diego, CA) and antibody binding was detected with
n) using an enhanced chemiluminescence system (GE Healthcare
s scanned in gray scale at the maximum resolution of at least 600 dpi
of total-eNOS were used. Data represent mean ± SEM. †p < 0.05
cle, according to the Kruskal–Wallis test.
Figure 4 Gene expression in aorta (upper panel), perivascular fat (middle panel), and soleus muscle (lower panel). Samples isolated from
male KKAy mice fed standard moderate-fat (MF) diet (black bars) and MF diet mixed with 0.005% candesartan cilexetil (gray bars) or 0.005%
azilsartan (shaded bars) for 3 weeks since 8–10 weeks of age, were analyzed by semiquantitative RT-PCR. Gapdh was used as an internal control.
Values shown represent mean ± SEM (n = 4–6).†p < 0.05 compared to C57BL/6 J and +p < 0.1 and *p < 0.05 compared to KKAy-vehicle according
to either the Kruskal–Wallis test or unpaired t test. TNFα: tumor necrosis factor α; MCP1: monocyte chemotactic protein 1; PPARγ: peroxisome
proliferator–activated receptor γ2; IRS-1: insulin receptor substrate 1; and Adipo: adiponectin.
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pared to candesartan cilexetil; (3) the differences in the ex-
pression levels of MCP1, F4/80, Nox2, and Nox4 of the
aortic wall and in the expression of TNFα in the perivas-
cular fat were attenuated by azilsartan compared to cande-
sartan cilexetil. These data suggest that azilsartan restores
endothelial function more effectively than does candesar-
tan cilexetil, by normalizing eNOS function and by redu-
cing inflammation and oxidative stress in diabetic mice.
Vascular endothelial dysfunction is implicated in the
pathogenesis of cardiovascular diseases [24] and is well
known to occur in obesity [31] and type 2 diabetes [9].
The present study compared the efficacy of azilsartan
and candesartan cilexetil on vascular reactivity, which
reflects eNOS inactivation [24-26], and we measured
phosphorylation of vascular eNOS as an indicator of
eNOS activity. Enzymatic activity of eNOS is regulated
by multiple phosphorylation of specific sites on the eNOS
protein [10]. When Ser1177 is phosphorylated, nitric oxide
production is increased 2- to 3-fold. In contrast, Thr495 is
a negative regulatory site of eNOS in that phosphorylationleads to decreased enzymatic activity [10]. It has been re-
ported that phosphorylation of Ser1177-eNOS is decreased
in diabetic rats [32] and diabetic patients [33]. Inversely,
eNOS phosphorylation at Ser495 was reported to be in-
creased in db/db diabetic mice [34]. These data are con-
sistent with our results showing that diabetic KKAy mice
have a tendency for lower phosphorylation at Ser1177 and
stronger phosphorylation at Thr495; these mice show a sig-
nificantly decreased phosphorylation ratio of Ser1177 to
Thr495 on eNOS compared to control C57BL6J mice. The
Ser1177/Thr495 ratio was effectively normalized (increased)
by azilsartan treatment compared to candesartan cilexetil.
The kinases AMPK, Akt, protein kinase A (PKA), calmodu-
lin/Ca2+ dependent protein kinase (CaMKII), protein kinase
G (PKG) and the phosphatase protein phosphatase 2A
(PP2A) have all been implicated in the regulation of
eNOS-Ser1177 phosphorylation [10], while protein kin-
ase C (PKC) has been shown to phosphorylate eNOS-
Thr495. In addition, there is evidence for co-ordination
between dephosphorylation of eNOS-Thr495 and activating
phosphorylation of eNOS-Ser1177 [35]. The mechanism(s)
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in the diabetic state are largely unknown, however, altered
signaling in AMPK, Akt, PKA, CaMKII, PKG, PP2A,
and PKC in the diabetic state could be involved in the
deregulated eNOS phosphorylation.
In the aortic wall of KKAy mice, mRNA expression
levels of MCP1 and F4/80 tended to be increased, sug-
gestive of overproduction of proinflammatory cytokines
by activated macrophages/monocytes. Such proinflamma-
tory cytokines frequently cause overproduction of ROS via
excessive stimulation of reduced nicotinamide adenine
dinucleotide phosphate [36]. Cellular sources of ROS in-
clude NADPH-dependent oxidases, xanthine oxidase, lipox-
ygenases, mitochondrial oxidases, and NO synthases [37].
NADPH oxidase (Nox) is a major source of ROS in diabetic
humans [38] and diabetic animals [39]. Seven isoforms of
Nox have been described in mammals [36]. Each isoform
contains a core catalytic subunit, i.e., Nox1–Nox5 and dual
oxidase (DUOX) 1 and DUOX 2 [36]. Each Nox catalytic
isoform contains up to 5 regulatory subunits that determine
1) maturation and expression of Nox and DUOX subunits
in biological membranes, 2) enzyme activation, and 3)
spatial organization. In our study, mRNA expression
levels of Nox2 (gp91phox), the major catalytic component
of endothelial NADPH oxidase, and Nox4, a component
of endothelial and smooth muscle NADPH oxidase [36],
were increased, suggesting that ROS production is in-
creased via overexpression of Nox2 and Nox4 in KKAy
mice. Reportedly, a siRNA-mediated knockdown of Nox2
(which is upregulated in diabetic endothelial cells) reduces
ROS production and improves vascular function [14]. It
has also been reported that Nox4 is upregulated in an ani-
mal diabetic model [40] or as a result of hyperglycemia
[41], with a concomitant increase in ROS. Taken together,
upregulation of Nox2 and/or Nox4 in the aorta may be
linked to ROS overproduction and vascular dysfunction
in our murine model of diabetes.
The upregulation of ROS-producing Nox2 and Nox4
was decreased strongly by azilsartan as compared to
candesartan cilexetil, according to the present results.
We could not determine whether the greater inhibition
of aortic Nox2 and Nox4 expression by azilsartan sig-
nificantly sensitizes endothelial vasodilator response to
acetylcholine. Angiotensin II levels are increased in pa-
tients with diabetes [42] and hyperglycemia potently
upregulated expression of the angiotensin II type 1 recep-
tor (AT1) [43]; thus, both could sensitize vascular cells to
angiotensin II. Oak and Cai reported that streptozotocin-
induced diabetes in mice is characterized by a marked
increase in aortic ROS production, which is inhibited by
NG-nitro-L-arginine methyl ester hydrochloride (L-NAME,
inhibitor of nitric oxide synthase) in contrast to nondiabetic
controls, indicating uncoupling of eNOS in the diabetic
state [44]. According to their data, angiotensin II receptortype 1 blocker candesartan decreased eNOS-derived ROS
while augmenting nitric oxide bioavailability in diabetic
aortas, which is suggestive of recoupling of eNOS. Nox ac-
tivity was more than doubled in the endothelium-denuded
diabetic aortas but this effect was attenuated by candesar-
tan, indicating that Nox remains active in nonendothelial
vascular tissues, although uncoupled eNOS is responsible
for endothelial production of O2. They concluded that the
dual effect on uncoupled eNOS and Nox might explain
the high efficacy of angiotensin II antagonists in restoring
endothelial function [44].
Going back to our results, because azilsartan has higher
affinity for and slower dissociation from AT1 receptors [22]
and shows stronger inverse agonism [23], these effects of
azilsartan on AT1 receptor, as compared with candesartan
cilexetil, may underlie the superior efficacy in diabetic
vascular dysfunction via the dual effect on uncoupled
eNOS and Nox. There is a report showing that angiotensin
II-induced contraction was augmented in aorta rings iso-
lated from diabetic rats and suggesting that the enhanced
functional coupling of AT1 receptors results in supersensi-
tivity to Ang II [45]. The higher affinity of azilsartan for
AT1 receptors may be beneficial for protecting angiotensin
II-induced vascular remodeling in the diabetic condition
[42]. Clinical studies have exhibited that some benefits con-
ferred by ARBs may not be class effects, but rather molecu-
lar effects [46]. It was shown in a clinical study that in
losartan users uric acid levels decrease from baseline, while
they increase in users of other ARBs like valsartan, telmisar-
tan, candesartan, and olmesartan [47]. Among these ARBs,
losartan uniquely exhibits a cis-inhibitory effect on the up-
take of uric acid by the renal uric acid transporter (URAT1)
[48]. Partial chemical structures for the URAT1 competitive
binding may involve an AT1 receptor-independent mech-
anism of action [48]. In our study, plasma levels of uric acid
increased comparably in KKAy mice treated with vehicle,
candesartan cilexetil, or azilsartan as compared to C57BL/
6 J, indicating no difference in uric acid metabolism be-
tween two ARBs. It has been reported that genetic disrup-
tion or pharmacological inhibition by telmisartan of the
AT1R attenuates atherosclerosis and improves endothelial
function in diabetic ApoE−/− mice via the PPARγ pathway
[49]. In 3 T3-L1 preadipocytes, azilsartan enhanced adipo-
genesis as well as effects on expression of PPARα, PPARδ,
leptin, adipsin, and adiponectin [50]. Azilsartan also po-
tently inhibited vascular cell proliferation in the absence of
exogenously supplemented angiotensin II or in cells lacking
AT1 receptors [50]. These findings suggest that azilsartan
can function as a pleiotropic ARB with beneficial effects on
actions that could involve more than just blockade of AT1
receptors and/or beyond their antihypertensive effects.
In the perivascular fat, mRNA expression levels of
TNFα, MCP1, and Nox2 were increased in KKAy, and
the overexpression of TNFα and Nox2 was attenuated
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decreased in KKAy, but was not altered by candesartan
cilexetil and azilsartan. We previously demonstrated that
adiponectin secreted from perivascular adipose tissue has a
protective role in neointimal formation after endovascular
injury thanks to its anti-inflammatory properties, whereas
perivascular adipose tissue–secreted TNFα plays an adverse
atherogenic role in neointimal formation because of its
proinflammatory effects [51,52]. Kurata et al. reported that
blockade of angiotensin II receptor ameliorates adipocyto-
kine dysregulation and that such action is mediated, at
least in part, by a reduction of oxidative stress in accumu-
lated adipose tissue [20]. In agreement with the previous
report, mRNA expression of TNFα, MCP1, and Nox2 was
increased in the perivascular fat from KKAy mice, and
these anomalies in the expression of TNFα and Nox2 were
attenuated only by azilsartan. Although the current study
could not verify the direct link between vascular dys-
function and attenuation of adipocytokine dysregulation
in perivascular fat, the possible role of perivascular fat in
azilsartan-induced vascular remodeling should be assessed
in future studies.
Although weight in the liver was increased, weight in
the soleus and quadriceps muscle was decreased in the
KKAy mice. A relative decrease of muscle mass as
compared to body weight fails to metabolize abundant
fat and worsens fat accumulation in the liver. Abun-
dant fat with concomitant metabolic derangement un-
derlies vascular dysfunction in the KKAy diabetic mice
[53,54]. In the soleus muscle of KKAy, mRNA expres-
sion levels of TNFα, MCP1, and Nox2 were increased
and IRS-1 was decreased, but this overexpression was
not attenuated by either candesartan cilexetil or azil-
sartan. It has been shown that azilsartan reduced left
ventricular hypertrophy, cardiac fibrosis, plasminogen
activator inhibitor-1 (PAI-1; a marker of profibrosis) in
aortic banding mice fed high-fat diet [55], indicating
that azilsartan may exert favorable biological effects in
non-diabetic obese insulin-resistant condition, which
shares a common mechanism such as enhanced ROS/
inflammation signals with the current model.Conclusions
Our data suggest that azilsartan restores endothelial func-
tion more effectively than does candesartan cilexetil, by
normalizing eNOS function and by reducing inflammation
and oxidative stress in diabetic mice.
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